- ►endojournals.org A Mari, WM Sallas, YL He, C Watson, M … - Journal of Clinical …, 2005 - Endocrine Soc Results: Vildagliptin significantly increased the insulin secretory rate at 7 mmol/liter glucose
(secretory tone), calculated from the dose response; the difference in least squares mean (
LSM) was 101 ± 51 pmol·min –1 ·m –2 (P = 0.002). The slope of the ß-cell dose response, ... Cited by 198 - Related articles - BL Direct - All 8 versions
- ►rh.dk [PDF] LL Baggio, DJ Drucker - Gastroenterology, 2007 - Elsevier This review focuses on the mechanisms regulating the synthesis, secretion, biological
actions, and therapeutic relevance of the incretin peptides glucose-dependent insulinotropic
polypeptide (GIP) and glucagon-like peptide-1 (GLP-1). The published literature was ... Cited by 179 - Related articles - All 25 versions
- ►diabetesjournals.org CF Deacon - Diabetes, 2004 - Am Diabetes Assoc Glucagon-like peptide (GLP)-1 is an incretin hormone with potent glucose-dependent insulinotropic
and glucagonostatic actions, trophic effects on the pancreatic β-cells, and inhibitory effects on
gastrointestinal secretion and motility, which combine to lower plasma glucose and ... Cited by 155 - Related articles - BL Direct - All 5 versions
- ►diabetesjournals.org J Mu, J Woods, YP Zhou, RS Roy, Z Li, E Zycband, Y … - Diabetes, 2006 - Am Diabetes Assoc Inhibitors of dipeptidyl peptidase-4 (DPP-4), a key regulator of the actions of incretin
hormones, exert antihyperglycemic effects in type 2 diabetic patients. A major unanswered question
concerns the potential ability of DPP-4 inhibition to have beneficial disease-modifying ... Cited by 127 - Related articles - BL Direct - All 9 versions
- ►physiology.org JJ Holst - Physiological reviews, 2007 - Am Physiological Soc Glucagon-like peptide 1 (GLP-1) is a 30-amino acid peptide hormone produced in the intestinal
epithelial endocrine L-cells by differential processing of proglucagon, the gene which is expressed
in these cells. The current knowledge regarding regulation of proglucagon gene ... Cited by 119 - Related articles - BL Direct - All 5 versions
CF Deacon, B Ahrén, JJ Holst - eid, 2004 - informahealthcare.com Inhibitors of the enzyme dipeptidyl peptidase IV (DPP IV) are of increasing interest to both diabetologists
and the pharmaceutical industry alike, as they may become established as the next member
of the oral antidiabetic class of therapeutic agents, designed to lower blood glucose and, ... Cited by 102 - Related articles - All 7 versions
AK Bose, MM Mocanu, RD Carr, CL Brand, DM Yellon - Diabetes, 2005 - Am Diabetes Assoc Glucagon-like peptide 1 (GLP-1), a gut incretin hormone that stimulates insulin secretion, also
activates antiapoptotic signaling pathways such as phosphoinositide 3-kinase and mitogen-activated
protein kinase in pancreatic and insulinoma cells. Since these kinases have been shown ... Cited by 102 - Related articles - All 12 versions
- ►tufts.edu [PDF] LL Baggio, DJ Drucker - 2006 - Annual Reviews Type 2 diabetes is characterized by hyperglycemia resulting from insulin resistance in the setting
of inadequate β-cell compensation. Currently available therapeutic agents lower blood glucose
through multiple mechanisms but do not directly reverse the decline in β-cell mass. ... Cited by 78 - Related articles - BL Direct - All 10 versions
MC Riddle, DJ Drucker - Diabetes Care, 2006 - Am Diabetes Assoc Current therapies for type 2 diabetes are frequently associated with inadequate control of postprandial
hyperglycemia, weight gain, and, in the case of oral agents, loss of efficacy over time. A better
understanding of physiological responses to meals is leading to the development of new ... Cited by 72 - Related articles - BL Direct - All 10 versions
